Developing a robust pipeline of biosimilar products
Biosimilar Products
Our portfolio of biosimilar products is in the advanced stages of commercial development. We have a strong and sustainable pipeline of high value biosimilar programs with a primary focus on Oncology and Immunology therapeutic segments.
Dazublys™, our Trastuzumab biosimilar, has received marketing authorization approval in India and is under review with EMA.
Stage Complete
In Progress
Next Stage
BP14
MOLECULE
PEGFILGRASTIM
Therapeutic Segment
ONCOLOGY
Development
Phase 1
Filing
Approval
Launch
Learn More
BP13
MOLECULE
FILGRASTIM
Therapeutic Segment
ONCOLOGY
Development
Phase 1
Filing
Approval
Launch
Learn More
BP01
MOLECULE
BEVACIZUMAB
Therapeutic Segment
ONCOLOGY
Development
Phase 1
Phase 3
Filing
Product filed using an abbreviated licensure pathway with Phase I data.
Approval
Launch
Learn More
BP02
MOLECULE
TRASTUZUMAB
Therapeutic Segment
ONCOLOGY
Development
Phase 1
Phase 3
Filing
Approval
Launch
Learn More
BP05
MOLECULE
RANIBIZUMAB
Therapeutic Segment
OPHTHALMOLOGY
Development
Phase 3
Filing
Approval
Launch
Learn More
BP11
MOLECULE
OMALIZUMAB
Therapeutic Segment
RESPIRATORY AND DERMATOLOGY
Development
Phase 1
Phase 3
Filing
Approval
Launch
Learn More
BP16
MOLECULE
Denosumab
Therapeutic Segment
Orthopaedic
Development
Phase 1
Phase 3
Filing
Approval
Launch
Learn More
BP08
MOLECULE
Tocilizumab
Therapeutic Segment
Immunology
Development
Phase 1
Phase 3
Approval
Launch
Learn More
BP38
MOLECULE
Ustekinumab
Therapeutic Segment
Immunology
Development
Phase 1
Phase 3
Filing
Approval
Launch
Learn More
BP27
MOLECULE
Undisclosed
Therapeutic Segment
Oncology
Development
Phase 1
Phase 3
Filing
Approval
Launch
BP33
MOLECULE
Undisclosed
Therapeutic Segment
Haematology
Development
Phase 1
Phase 3
Filing
Approval
Launch
CuraTeQ’s product portfolio comprises of ‘4 more biosimilars’ and ‘4 vaccines’ at different stages of development.
Latest News
12 November 24
EMA grants GMP certificate to CuraTeQ Biologics’ manufacturing facility in Hyderabad
Read More
15 March 24
CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar
Read More
17 February 24
Auro Peptides completes US FDA inspection with zero observations
Read More
17 January 24
CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India
Read More
20 November 23
CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector
Read More
10 July 23
CuraTeQ Biologics to market Ustekinumab biosimilar to treat Crohn’s disease, arthritis
Read More
05 July 23
CuraTeQ Biologics announces positive Phase-3 results for Trastuzumab biosimilar
Read More
12 January 22
Aurobindo Pharma arm CuraTeQ expands scope of biosimilars distribution pact with Orion
Aurobindo Pharma on Tuesday said its subsidiary CuraTeQ Biologics has expanded the scope…
Read More
12 February 17
Aurobindo Pharma forays into biosimilars development
Aurobindo Pharma Limited is pleased to announce the acquisition of four cell culture derived biosimilar…
Read More